Smith+Nephew to showcase latest Orthopaedic advancements in Cementless Knees, Total Hip Arthroplasty and Robotics at AAOS 2022 Annual Meeting

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces it will it showcase its latest innovations for Orthopaedic Reconstruction and Robotics during the American Academy of Orthopaedic Surgeons 2022 Annual Meeting being held in Chicago, IL.

Introducing the Smith+Nephew Cementless Knee Continuum of Care

Cementless knee implants are serving a resurgent segment¹ driven by the potential for better long-term fixation through biologic integration^2,3, shorter operating times⁴, and the shift to Ambulatory Surgery Centers (ASCs).⁵ Smith+Nephew is now the only company in the US with a cementless commercial offering for total knees with the recent launch of the LEGION^◊ CONCELOC^◊ Cementless Total Knee System - and partial knees with the acquisition of Engage Surgical and the ENGAGE^◊ Cementless Partial Knee System earlier this year.

As the only medical device company with a complete cementless knee portfolio, Smith+Nephew is uniquely positioned to accommodate whatever a patient or surgeon may need - a total knee with CONCELOC Advanced Porous Titanium 3D printing technology and the LEGION Knee System’s clinical success^{6-8 *} treating over two million patients, or a partial cementless knee implant optimized for robotics-assisted surgery and ideal for the ASC environment. 

Minimally Invasive Anterior Approach for Total Hip Arthroplasty

A recent study of over 6,000 Total Hip Arthroplasty (THA) procedures concluded that Smith+Nephew’s ABLE^◊ Advanced Anterior Approach for THA is a minimally invasive, muscle-sparing approach which drives efficiency with few complications and no barriers to adoption.⁹

The high-quality, low-cost ABLE Approach to THA complements a value-based system of limiting healthcare dollar spend while maintaining or improving patient outcomes.⁹ It allows the surgeon considerable flexibility by performing the procedure either supine or lateral, with or without fluoroscopy, and using any femoral and acetabular components.

 

Real Intelligence and Robotics-assisted Surgery Advancements

Smith+Nephew continues to broaden the capabilities of its handheld robotic-assisted technology and digital ecosystem. The CORI^◊ Surgical System has expanded indications to address needs in Total Hip Arthroplasty with RI.HIP NAVIGATION - a new application on CORI designed to help maximize accuracy and reproducibility by delivering patient-specific component alignment. When combined with complimentary tools for case planning, patient functional assessment, and RI.HIP MODELER**, the CORI System delivers a comprehensive navigation solution for hips. RI.INSIGHTS, a cloud-based global data management platform that enables surgeons to readily apply insights from their robotic-assisted procedures will also be showcased with additional enhancements.

The CORI System is the only 2^nd generation robotics platform in the orthopaedic knee market and its global footprint continues to expand with recent approvals in Europe and Japan. It is small**, portable†, affordable¹⁰ and unlike other robotic systems, it eliminates time, costs, and radiation exposure¹¹ associated with preoperative CT imaging. Instead, the CORI System uses image-free smart mapping to build patient-specific 3D models of the anatomy in surgery.

To learn more about the latest advancements in orthopaedic reconstruction and robotics, please stop by the Smith+Nephew booth (#831) during AAOS 2022.

Enquiries

Media
David Snyder	+1 978-749-1440
Smith+Nephew

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

 

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.}

^{◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.}